MK0653, ezetimibe

Phase 3Small molecule

OOrganon and Co

MK0653, ezetimibe is one of 72 small molecule programs targeting Hyperlipidemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HyperlipidemiaActive, not recruiting

SitosterolemiaActive, not recruiting

Heart DiseaseActive, not recruiting

HyperlipidemiaPhase 3

Active, not recruiting

SitosterolemiaPhase 3

Active, not recruiting

Heart DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

166 competitors in Heart Disease

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

9 2

Lopid

Pfizer

Phase 3

1 3

Biaxin

AbbVie

Phase 3

1 4

Depo-Provera

Activella

Zoloft

VViatris Specialty LLC

Phase 3

2 7

Vivarin

HHikma Pharmaceuticals LLC

Phase 3

1 8

Comparator: Statins

Merck & Co.

Phase 3

1 9

Zesly

MMezzion Pharma Co. Ltd

Phase 3

—10

Levophed

GGeneral Hospital of Ningxia Medical University

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Heart Disease5 trials

A Study Comparing Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Patients at Risk for Heart Disease (0653-023)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00551447·616 enrolled

An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092638·450 enrolled

Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)

Completed·OOrganon and Co·Phase 3·NCT00092625·442 enrolled

Show 2 more trials

Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)

Completed·OOrganon and Co·Phase 3·NCT00092599·410 enrolled

Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092612·372 enrolled

Sitosterolemia3 trials

Sitosterolemia Extension Study (0653-003)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092807·37 enrolled

Sitosterolemia Extension Study (0653-004)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092820·58 enrolled

An Investigational Drug Study to Lower Non-Cholesterol Sterol Levels Associated With Sitosterolemia (0653-062)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092898·30 enrolled

Cholesterol2 trials

Comparing an Investigational Medication Versus an Approved Medication in Reducing Cholesterol Levels (0653-025)

Completed·OOrganon and Co·Phase 3·NCT00092716·655 enrolled

Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)

Completed·OOrganon and Co·Phase 3·NCT00092586·2,904 enrolled

Hyperlipidemia2 trials

Two Investigational Drugs in Patients With Mixed Hyperlipidemia (0653-036)

Completed·OOrganon and Co·Phase 3·NCT00092560·587 enrolled

Study of Ezetimibe and Fenofibrate in Patients With Mixed Hyperlipidemia (0653-036)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00092573·576 enrolled

Type 2 Diabetic Patients1 trial

Study Evaluating the Efficacy and Safety of Simvastatin Alone Compared With Simvastatin Plus Ezetimibe in Type 2 Diabetic Patients (0653-021)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00551876·214 enrolled

2 more indications

Statin1 trial

Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED)

Completed·OOrganon and Co·Phase 3·NCT00395473·141 enrolled

Observational Study1 trial

Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)

Completed·OOrganon and Co·Phase 3·NCT00457275·440 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for MK0653, ezetimibe. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MK0653, ezetimibe compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MK0653, ezetimibe. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Organon and Co company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOrganon and Co

MK0653, ezetimibe

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Heart Disease5 trials

Sitosterolemia3 trials

Cholesterol2 trials

Hyperlipidemia2 trials

Type 2 Diabetic Patients1 trial

Statin1 trial

Observational Study1 trial

References

Drug Info

Quick Facts

Related News